Urolithiasis Management Devices Market expected to rise to US$1.78 bn up to 2024

The global demand for urolithiasis management devices has seen a steady rise in the past few years owing to the increasing prevalence of kidney stones. A 2015 study by the National Kidney Foundation of the U.S. states that one in 10 people in the country has kidney stones and that more than a half a million people are admitted to emergency rooms for kidney stone management every year. Across the globe as well, factors such as obesity, rising geriatric population, which is highly susceptible to kidney stones owing to reduced renal function and diabetes, and change in lifestyles are contributing to increased prevalence of kidney stone formation.

Transparency Market Research estimates that the global urolithiasis management devices market will exhibit a healthy 4.5% CAGR over the period between 2016 and 2024 and rise to a valuation of US$1.78 bn by 2024.

Read Full Report: http://www.transparencymarketresearch.com/urolithiasis-management-devices-market.html

Clinics and Ambulatory Surgical Centers to Remain Dominant End-use Segments

Of the key end-users of urolithiasis management devices, including hospitals, ambulatory surgery centers (ASCs), and clinics, the segment of clinics led the global market in terms of both revenue and volume in 2015. In terms of revenue, the segment accounted for over 55% in the said year. The leading position of the market segment can be attributed to factors such as the significant rise in the number of people opting for urolithiasis surgeries and advancements in treatment options that have reduced the time required for undertaking the procedures. Over the period between 2016 and 2024 as well, the segment is expected to hold a commanding position in the global market, retaining its status as the leading revenue generator.

The demand for urolithiasis management devices across ambulatory surgical centers is expected to exhibit a strong growth over the next few years, with the end-user segment emerging as one of the most promising investment grounds for the global urolithiasis management devices market. The segment is expected to exhibit strong growth owing to high demand for ambulatory surgical centers and preference for day care surgeries across developing as well as developed parts of the world. Applications of urolithiasis management devices across the hospitals end-use segment is expected to witness stagnant growth as clinics and ambulatory surgical settings become more preferred owing to the lower cost of treatment and the need to be hospitalized for shorter lengths of time.

Rising Geriatric Population in Asia Pacific to Stimulate Increased Adoption

North America held a dominant share of nearly 36% in the global urolithiasis management devices market in 2015. Factors such as the rising prevalence of kidney stone, rising geriatric population, and campaigns undertaken to raise awareness about the risks associated with kidney stones by government bodies are central to the growth of the market in the region. Additionally, the introduction of new and innovative urolithiasis management devices such as laser lithotripters and flexible ureterenoscopes have also aided the healthy growth of the North America urolithiasis management devices market. The presence of high disposable income groups across developed economies such as the U.S. and Canada in North America, with a high prevalence of lifestyle-induced diseases such as obesity and a large base of geriatric population have also influenced the increased adoption of urolithiasis management devices.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2252

The urolithiasis management devices market in Asia Pacific is expected to exhibit an impressive CAGR of 4.6% over the period between 2016 and 2024. The mounting geriatric population in the region is the key factor driving the urolithiasis management devices market in the next few years. According to the United Nations ESCAP (Economic and Social Commission for Asia and the Pacific), is region is presently home to more than half of the world’s population of people aged over 60 years and the number is expected to rise to more than 2.45 bn by 2050. Owing to this, the regions is expected to lead to a substantial rise in demand for urolithiasis management devices in the next few years.

Some of the key vendors operating in the global urolithiasis management devices market are C. R. Bard, Inc., Allengers Medical Systems Ltd, Dornier Medtech GmbH, Boston Scientific Corporation, Cook Group, Inc., Electro Medical Systems S.A., DirexGroup, Olympus Corporation, Karl Storz, and Siemens Healthcare.

Compression Therapy Market: North America Exhibits Highest Prospects for Compression Therapy

Transparency Market Research forecasts the global compression therapy market to reach US$4.25 bn by 2024 from a valuation of US$2,693.4 mn in 2015. If these figures hold true, the market will exhibit a CAGR of 5.3% between 2016 and 2024.

Prevalence of Obesity Creates Ample Opportunities for Expansion of Compression Therapy Market in Developed Economies

The American Academy of Orthopedic Surgeons (AAOS) has stated that around 129,000 knee arthroplasty surgeries were conducted in the U.S. in 1990. The number had reached over 600,000 surgeries in 2010. Furthermore, the AAOS projects the number of arthroplasty surgeries to be conducted in the U.S. by 2030 to surpass 3 million. Considering the incredible rise in number of cases reported in the U.S. alone, the incidence of orthopedic conditions globally is projected to increase at a rapid pace. This creates ample opportunities for the expansion of the compression therapy market.

Read Full Report: http://www.transparencymarketresearch.com/compression-therapy-market.html

As obesity increases the risk of vascular diseases due to the pressure exerted by the bodyweight on underlying organs, its rising prevalence is often linked with the increasing demand for compression therapy. As per the World Health Organization (WHO), the prevalence of obesity has nearly doubled since 1980. With experts projecting the number to surge during the report’s forecast period, opportunities for the global compression therapy market are likely to bolster.

Lack of proper reimbursement policies will, however, limit the market’s success to an extent, finds TMR. Nevertheless, the rising investments in emerging economies and widespread unmet medical needs in these countries will support the market’s growth in the near future.

North America Emerges Dominant with Most Attractive Opportunities

Regionally, North America has been exhibiting the most lucrative prospects for leading enterprises in the market. The region held around 47.2% of the market in 2015, followed by Europe, which accounted for a share of 32.2% in the market in the same year. The prevalence of vascular diseases in both these regions is relatively higher. In North America, TMR finds the alarming rate of obesity as a prime driver of the compression therapy market. Among other regions exhibiting prospects for the compression therapy market, Asia Pacific is expected to report the highest CAGR.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1537

Some of the prominent companies operating in the global compression therapy market include 3M Health Care, Bio Compression Systems, Inc., BSN Medical, Covidien plc, Paul Hartmann AG, and others.

Supported by Clinical Evidence, Static Compression Therapy Emerges as Dominant Market Segment

Demand for static compression therapy is forecast to rise at a rapid pace. The segment in 2015 held the largest share in the market and is expected to sustain its dominant position through the forecast period. The low cost and easy availability of static compression products have consequently boosted their sales. These products are also supported by clinical evidence, due to which doctors around the world seem to prefer static garments more. Besides this, the aesthetic appearance and comfortable material of static compression hosiery have made them a preferred choice among patients.

Women’s Health Rehabilitation Products Market: Rising Geriatric Population Boosts Demand for Treat Urinary Incontinence Products

This research report provides a detailed analysis of the women’s health rehabilitation products market and helps understand various factors that drive the market. The market overview section analyzes market dynamics and trends such as drivers, restraints and opportunities that influence the current nature and future status of the market. Porter’s Five Forces Analysis has been covered in terms of bargaining power of buyers and suppliers, threat of new entrants and substitutes, and competitive rivalry in the global casting and splinting market. Value chain analysis and other market dynamics factors such as market attractiveness analysis have also been explained in order to deliver a thorough analysis of the overall competitive scenario of the global women’s health rehabilitation products market. This section of the report also includes key players’ product wise heat map analysis in 2015 for this market.

Surging at a CAGR of 5.0% between 2016 and 2024, the women’s health rehabilitation products market is expected to reach US$4.2 bn by 2024. The market stood at a valuation of US$2.6 bn in 2015.

Read Full Report: http://www.transparencymarketresearch.com/womens-health-rehabilitation-products-market.html

Rehabilitation has emerged as an important method of mitigating the burgeoning risk of chronic diseases among women. These services are designed to improve the overall heart health, increase metabolism, expedite faster recovery, and improve hormonal profile among ailing women. Their demand has thus increased in response to the drastically changing lifestyle and dietary preferences. Integration of advanced technologies in existing rehabilitation products has further boosted prospects for their sales.

Earlier, acceptance of health rehabilitation services was a major issue across developed nations, which is now resolved with the rising awareness. However high product pricing still creates major bottlenecks for the sales of health rehabilitation products in emerging economies.

North America, Trailed by Europe, Emerged Key Contributors in 2015

Regionally, North America emerged as the key contributor in the global health rehabilitation products market in 2015, trailed by Europe. The market in North America is expected to reach US$1.5 bn by the end of 2024, from US$1 bn in 2015, rising at a CAGR of 4.9% during the period. High demand for women health rehabilitation products in both Europe and North America is attributed to the increasing number of road accidents in the last few years and the rising geriatric population. However, TMR projects Asia Pacific to exhibit the fastest CAGR due to the presence of untapped opportunities in the region. Besides this, Asia Pacific boasts a developing health care infrastructure and strong presence of skilled health care professionals, which is expected to drive demand for women health rehabilitation products in the region.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13022

Rising Geriatric Population Boosts Demand for Treat Urinary Incontinence Products

By product type, orthopedic, pelvic pain product, urinary incontinence, pregnancy and postpartum, lymphedema, breast cancer, and osteoporosis constitute the major segments in the global women health rehabilitation products market. Of these, urinary incontinence held the dominant share in the market in 2015. It is also projected to maintain its lead through the forecast period. Increasing urinary incontinence among aged women is expected to keep demand from this segment high in the forthcoming years. The segment is expected to report a CAGR of 5.4% during the forecast period.

Some of the leading players operating in the global women health rehabilitation products market include Access Health (Victoria, Australia), Carib Rehab Ltd. (St. Michael, Barbados), GE Healthcare (Chalfont St. Giles, U.K.), GPC Medical Ltd.( New Delhi, India), Pelvic Health and Rehabilitation (San Francisco, U.S.), Rehab Plus (Timmins, Canada), Meyer Physical Therapy (New York, U.S.), Sportstek (Oakleigh, Australia), Vandana Surgical Cotton Ind. (Ajmer, India), and Win Health Medical Ltd. (Jedburgh, U.K.)

Tourniquet Market: Rising Number of Road Accidents Uphold Need for Tourniquet Systems in Emergency Healthcare Services

The tourniquet market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market which is divided by product, application, end-user and geography. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. This section of the report also provides with market attractiveness analysis, and Porter’s Five Forces analysis providing a thorough analysis of the overall competitive scenario in the global tourniquet market.

A rising number of road accidents and government interventions aimed at improving the healthcare infrastructure in developing regions are the major factors that will provide major impetus to the global tourniquet market in the coming years.

Technological advancements and the introduction of disposable tourniquet cuffs will also play a major role in pushing the market further in the coming years. TMR findings project that the market holds an opportunity of US$408.6 mn by 2023. The market, which valued US$184.6 mn in 2014, will expand at a favorable CAGR of 9.3% over the period between 2015 and 2023.

Read Full Report: http://www.transparencymarketresearch.com/pressrelease/tourniquet-market.htm

Rising Concerns about Infections from Disposable Cuffs Prove Beneficial for Reusable Tourniquet Cuffs

The concerns about the risk of infection through the use of reusable tourniquet cuffs on multiple patients has been a major challenge for the global tourniquet market in the past years. The concerns have fared well for disposable tourniquet cuffs. Despite the fact that these products must be disposed of after single use, slightly adding to the overall costs of a surgery, are gaining increased adoption across several regional markets.

The market for disposable tourniquet cuffs is projected to exhibit a CAGR of 9.9% from 2015 to 2023. The segment of reusable tourniquet cuffs, cashing in on its immense popularity, will still manage to grow at a rather favorable 9.1% CAGR over the same period. Durability and cost-efficiency of reusable tourniquet cuffs will help the segment sustain through the tough times. Tourniquet systems, the devices that monitor inflation time of the cuff and regulate the pressure in response, will rise to a valuation of US$240.2 mn by 2023.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=11627

North America Leads due to Presence of Top Vendors and Increased Number of Accidents

On the geographic front, North America emerged as the clear leader in the tourniquet market in 2014, accounting for a share of 53.5%. The alarming rise in the number of road accidents and traumatic orthopedic injuries in the region helped the market achieve this monumental feat. Additionally, persistent attempts of government to improve awareness about the usage of technologically advanced tourniquet cuffs as an efficient first line of treatment have also supported the increased use of tourniquets across healthcare facilities in the region.

Europe acquired the second-largest, yet a comparatively modest 18.4%, share in the overall tourniquet market in 2014. Highly advanced emergency care infrastructure in the region is the major factor making Europe a promising regional market for tourniquet systems.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11627

However, Asia Pacific will present the most lucrative growth opportunities for the global tourniquet market from 2015 to 2023. The rising population of the middle class demographic, increased healthcare funds, and the demand for technologically advanced trauma care products will help the Asia Pacific tourniquet market exhibit a 9.9% CAGR during this period. The tourniquet market in Asia Pacific will also benefit from the rising number of hospitals and laboratory settings, and the entry of several medical device companies in the region.

The highly dynamic and competitive global market for tourniquets features the presence of a large number of vendors. Zimmer Biomet Holdings, Inc. is the leading vendor, followed by Stryker Corporation and Ulrich GmbH & Co. These companies have their businesses across all three major segments of the global tourniquet market. Other major vendors in the market are Pyng Medical Corporation, Hammarplast Medical AB, Delfi Medical Innovation, Inc., and VBM Medizintechnik GmbH.

Global Medical Sensors Market: Development of IT-based Medical Sensor Devices to Emerge as Growth Opportunity, says TMR

The global medical sensors market is fragmented with the top three companies collectively accounting for 23.3% of the market in 2014. These three companies are Honeywell International Inc., Danaher Corporation, and NXP Semiconductors. Some of the other players in the market are GE Measurement & Control, Analog Devices, Inc., Omni Vision Technologies, Inc., TE Connectivity Ltd., and Avago Technologies Limited. Players in the market are intent on providing novel and advanced technology based medical sensors, states a new report by Transparency Market Research (TMR). It is expected that many local manufacturers will capture significant market shares. The absence of external substitutes will ensure a low level threat of substitutes.

According to the report, the global medical sensors market is expected to rise from US$10,000.0 mn in 2014 to US$18,741.3 mn by 2023. On the basis of product, the biosensors segment led in the past and will continue to do so, and be worth US$9,202.5 mn. However, the squid sensors segment will expand at the maximum CAGR of 8.6% from 2015 to 2023. On the basis of application, the surgical segment will continue to remain dominant and be worth US$6,259.6. In addition to this, it is expected that the monitoring segment will expand at a healthy CAGR of 8% from 2015 to 2023.

Read Full Report: http://www.transparencymarketresearch.com/medical-sensors-market.html

Asia Pacific to Emerge as Lucrative Regional Market for Medical Sensors in Future

By end user, the hospitals segment will lead and be worth US$5,809.9 mn by 2023. The nursing home and home care segment is expected to expand at a 7.8% CAGR between 2015 and 2023. On the basis of geography, North America is leading in the medical sensors market and will continue to do so. The market in North America is expected to be worth US$6,371.9 mn by 2023. On the other hand, Asia Pacific medical sensors market will prove to be lucrative in the coming years and expand at an 8.2% CAGR between 2015 and 2023. “The growing interest of key companies to expand their presence in the developing nations of Asia Pacific is expected to drive the market in the region”, says a TMR analyst.

High Risk of Various Diseases among Growing Geriatric Population to Drive Demand for Medical Sensors

The increasing prevalence of diseases such as obesity, diabetes, kidney, respiratory, and cardiovascular diseases is driving the global medical sensors market. Thus, there is a high demand for reliable and accurate medical equipment for the growing patient population, which in turn is boosting the market for medical sensors. Sensors help in giving early warnings and lead to an accurate diagnosis of diseases and thus, their need will continue to remain in the coming years. The growing population of elderly people worldwide will be another driving factor for the medical sensors market. With age, the chances of having orthopedic diseases, neurological disorders, endocrine diseases, and oral diseases increases and this will create a heightened demand for medical devices and surgeries where real time sensors play a vital role. On the other hand, the high cost of medical sensors will act as a restraint.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=407

Emergence of IT-based Medical Devices to Create New Opportunities

The application of IT in medical industry has revolutionized treatment methods for various diseases. The introduction of medical electronics with features such as wireless and multimedia will create a heightened demand for medical sensors. Various players in the market are investing extensively in research and development so as to develop IT-based medical sensor devices. Moreover, IT has increased the scope of medical sensors in newer medical applications such as a digital pill or ingestible sensor pill for tracking drug delivery.

This information is based on the findings of a report published by Transparency Market Research titled “Medical Sensors Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 – 2019.”

Cerebrospinal Fluid (CSF) Management Market grows with growing medical tourism in emerging nations and rising geriatric population

Some of the key players in the global cerebrospinal fluid (CSF) management market are Medtronic plc, DePuy Synthes (a J & J Company), Sophysa S.A., Spiegelberg GmbH & Co. KG, B. Braun Melsungen AG, BeckerSmith Medical, Inc., Möller Medical GmbH, and Integra LifeSciences Holding Corporation. The global market for CFS management was valued at US$1.13 bn in 2014. Expanding at a healthy CAGR of 5.5% during the forecast period of 2015 to 2023, the revenue in the market is estimated to reach US$1.84 bn by the end of 2023.

In order to maintain their stronghold, these players actively focus on innovations and developments related to technology and application in the market for cerebrospinal fluid management in order serve the multi-dimensional needs of the consumers. For instance, Medtronic plc recently announced the clearance of StrataMR valves and shunts by the U.S. Food and Drug Administration (FDA). This is an addition to Medtronic portfolio of Strata Adjustable Valve Systems, which are used to treat patients with hydrocephalus and cerebrospinal fluid (CSF) disorders. The approval will help Medtronic to complete its portfolio of systems designed for access to full-body MRI, such as pacemakers, deep brain stimulation (DBS) systems, implantable cardioverter defibrillators (ICDs), and spinal cord stimulators.

Read Full Report: http://www.transparencymarketresearch.com/csf-management-market.html

Asia Pacific Emerging Lucrative Market

By type of product, the cerebrospinal fluid management market is segmented into CSF shunts and CSF drainage systems, which can be further sub-segmented into ventricular drainage system and lumbar drainage system. In 2014, CSF shunts were most in demand and, are expected to remain the dominant segment throughout the forecast period. Although, the segment of CSF drainage system is also projected for the strongest CAGR in the market. Geographically, the report studies the regional markets of North America, Europe, Asia Pacific, Latin America, and Rest of the World. North America contributed most of the demand for CSF management in 2014 and is likely to remain the most lucrative region during the forecast period. The report also rates Asia Pacific as a region that players could focus on, owing to factors such as increasing demand for minimally invasive surgeries, growing medical tourism in emerging nations, and rising geriatric population.

Increased Government Funding Supporting Growth

According to the United Nations (US), there were 841 million people aged over 60 in the world. The UN expects this number to exceed to 2 billion by the end of 2050. Since geriatrics generally suffer from neurological diseases such as Alzheimer’s and Parkinson’s, this exponential rise in geriatric population is the primary reason for the extending demand for CSF management. The report also observes overall rise in the incidences of neurological diseases, increased funding by government and private organizations, and the escalating demand for minimally invasive surgeries are some of the other factors that will support the growth rate in the global market for cerebrospinal fluid management. Conversely, risk of infection during surgery is expected to negatively influence the growth rate.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2590

The author of the report concedes, “The countries with emerging economies such as China, India, and Brazil comprise profitable future markets for CSF management. These nations have vast populations and the disposable income among the urban population is on the rise, which is enhancing their purchasing power.”

The information presented in this review is based on a Transparency Market Research report, titled, “Cerebrospinal Fluid (CSF) Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”

Scleroderma Diagnostics and Therapeutics Market: Physician and Patient Preference to make Immunosuppressive Agents Leading Drug Category

TMR estimates that the global scleroderma diagnostics and therapeutics market will expand at a CAGR of 9.7% from 2016 to 2024 and rise from US$1,633.5 mn in 2015 to US$3,663.7 mn by 2024.

Global Scleroderma Diagnostics and Therapeutics Market: Snapshot

The scleroderma therapeutics and diagnostics market exhibits high potential due to untapped needs and is set to grow rapidly in the near future due to the increasing focus globally on treatment of orphan diseases. The lack of approved drugs in the market makes it a highly opportune condition for players to convert their innovative drug ideas into successful treatment methods for this rare chronic inflammatory disease.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/scleroderma-diagnostics-therapeutics.htm

Physician and Patient Preference to make Immunosuppressive Agents Leading Drug Category

Presently, there is no approved drug for treatment of this orphan disease. Although drugs to manage symptomatic relief are available in the scleroderma therapeutics market, the treatment of scleroderma is challenging for a physician, since no two patients are alike in the progress of their disease. Thus, a host of different drugs are prescribed to every patient, depending on the extent, severity and nature of their symptoms.

It has been observed that patient consumption patterns in the global scleroderma diagnostics and therapeutics market are inclined towards immunosuppressive agents, which have shown to provide relief against several symptoms in both systemic and localized scleroderma cases. Moreover, of the very few treatments identified to efficaciously modify the course of scleroderma, physicians often recommend immunosuppressive agents to manage the most common symptoms of the disease. The segment, as a result, accounts for the dominant share in the global market.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2498

Prostacyclin analogues have been found to have a potent effect in treating systemic scleroderma patients who suffer from pulmonary arterial hypertension. However, these drugs are expensive and thus, even though a smaller sub-set of patients is administered with these agents, their market value is high. This segment grabbed over 8.0% share of the global scleroderma therapeutics market in 2015, and is anticipated to slightly decline by 2024 owing to availability of cheaper alternatives within this segment.

Developed Regions to Continue to Command Dominance

Owing to better diagnostic and treatment rates, in part due to proactive awareness-raising initiatives by various foundations, have aided North America and Europe gain the predominant share in the global scleroderma diagnostics and therapeutics market. North America accounted for a share of nearly 34.0% while Europe held nearly 30% of the global scleroderma therapeutics market in 2015. This is attributed to presence of renowned pharmaceutical companies, research organizations, and institutes in the regions, which are focused on finding a standard treatment for the condition.

The North America and Europe markets for scleroderma diagnostics and therapeutics are expected to retain their dominance in the global scleroderma diagnostics and therapeutics market throughout the forecast period, exhibiting CAGRs of 11.2% and 10.9%, respectively, over the period between 2016 and 2024. The ongoing cutting-edge research pertaining to scleroderma will aid the growth of a niche scleroderma diagnostics and therapeutics market in these regions.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2498

Asia Pacific represents some of the world’s key emerging economies, which have the potential to adopt quickly to new therapies, provided they are available at reasonable costs. Due to the price-sensitive nature of the market, as well as availability of cheaper generics and reasonable clinical diagnostic rates compared to North America and Europe, the market for Asia Pacific gained the third position in terms of market share in 2015. The Asia Pacific market will also retain its position in the global market over the forecast period, with factors such as large population and high unmet needs working in favor of market expansion in the region.

Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and Sanofi are some of the key players operating in the global scleroderma diagnostics and therapeutics market.